Exchange: NASDAQ·Updated 07:55 PM EDT
News
all
press releases
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.read more...
Benzinga
More News
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Zacks
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Key PointsDeep Track Capital bought 6,772,595 shares of Alumis last quarter; the estimated transaction value was $169.31 million (based on average prices...
Nasdaq News: Markets
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Key PointsCormorant bought 313,645 additional Alumis shares in the first quarter; the estimated trade size was $7.84 million (using average prices in the quarter...
Nasdaq News: Markets
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Key PointsOmega Fund Management sold 411,968 shares of Alumis; the estimated trade value is $10.3 million (based on quarterly average price...
Nasdaq News: Markets
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.read more...
Benzinga
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Why One Fund's $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Key PointsACT Capital Management acquired 174,250 ALMS shares in the first quarter, with an estimated trade value of $4.36 million based on average first-quarter pricing...
Nasdaq News: Markets
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -26.09% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.